Wedbush Starts TCR2 Therapeutics (TCRR) at Outperform

Go back to Wedbush Starts TCR2 Therapeutics (TCRR) at Outperform

SVB Leerink Starts TCR2 Therapeutics (TCRR) at Outperform

March 11, 2019 12:35 PM EDT

SVB Leerink analyst Johnathan Chang initiates coverage on TCR2 Therapeutics (NASDAQ: TCRR) with a Outperform rating and a price target of $27.00.

For an analyst ratings summary and ratings history on TCR2 Therapeutics click here. For more ratings news on TCR2 Therapeutics click here.

Shares of TCR2 Therapeutics closed at $15.64 yesterday.

... More

BMO Capital Starts TCR2 Therapeutics (TCRR) at Outperform

March 11, 2019 1:29 AM EDT

BMO Capital analyst Do Kim initiates coverage on TCR2 Therapeutics (NASDAQ: TCRR) with a Outperform rating and a price target of $37.00.

The analyst comments "We believe TCR2's TRuC platform for modified TCR-T cell therapies will exceed CAR-Ts in efficacy and potentially... More

Jefferies Starts TCR2 Therapeutics (TCRR) at Buy

March 11, 2019 1:10 AM EDT

Jefferies analyst Biren Amin initiates coverage on TCR2 Therapeutics (NASDAQ: TCRR) with a Buy rating and a price target of $31.00.

For an analyst ratings summary and ratings history on TCR2 Therapeutics click here. For more ratings news on TCR2 Therapeutics click here.

Shares of TCR2 Therapeutics closed at $15.64 yesterday.

... More